CollaGenex Pharmaceuticals Inc (NASDAQ: CGPI) announced that the results of a Phase 2 clinical trial of the therapeutical benefits of incyclinide for the treatment of rosacea did not meet expectations and further trials would be stopped.
Expectations were that the incyclinide would reduce inflammatory lesions in patients however results were no different from patients being administered a placebo.
Klaus Theobald, M.D., Ph.D., chief medical officer of CollaGenex, said, "We are surprised and disappointed that the results of this large, well-controlled Phase 2 study did not support the findings of an earlier, much smaller pilot study in rosacea patients. On the basis of these results, we will not be pursuing further clinical development of incyclinide in rosacea patients."
Theobald did state that Collagenex would continue work of incyclinide for acne patients due to efficiency and low side effects.
[Source: BioSpace]
Comment Preview